These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31071374)

  • 1. Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation.
    Park K; Skidmore S; Hadar J; Garner J; Park H; Otte A; Soh BK; Yoon G; Yu D; Yun Y; Lee BK; Jiang X; Wang Y
    J Control Release; 2019 Jun; 304():125-134. PubMed ID: 31071374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complex sameness: Separation of mixed poly(lactide-co-glycolide)s based on the lactide:glycolide ratio.
    Skidmore S; Hadar J; Garner J; Park H; Park K; Wang Y; Jiang XJ
    J Control Release; 2019 Apr; 300():174-184. PubMed ID: 30853529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of branched poly(lactide-co-glycolide) polymers used in injectable, long-acting formulations.
    Hadar J; Skidmore S; Garner J; Park H; Park K; Wang Y; Qin B; Jiang X
    J Control Release; 2019 Jun; 304():75-89. PubMed ID: 31054992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's Poly (Lactic-Co-Glycolic Acid) Research Program and Regulatory Outcomes.
    Wang Y; Qin B; Xia G; Choi SH
    AAPS J; 2021 Jun; 23(4):92. PubMed ID: 34189655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of semi-solvent effects for PLGA polymers.
    Garner J; Skidmore S; Hadar J; Park H; Park K; Kuk Jhon Y; Qin B; Wang Y
    Int J Pharm; 2021 Jun; 602():120627. PubMed ID: 33915188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical-Chemical Characterization of Octreotide Encapsulated in Commercial Glucose-Star PLGA Microspheres.
    Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Qin B; Schwendeman SP
    Mol Pharm; 2020 Nov; 17(11):4141-4151. PubMed ID: 32876463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse Engineering the 1-Month Lupron Depot®.
    Zhou J; Hirota K; Ackermann R; Walker J; Wang Y; Choi S; Schwendeman A; Schwendeman SP
    AAPS J; 2018 Oct; 20(6):105. PubMed ID: 30280294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Q1/Q2: The Impact of Manufacturing Conditions and Test Methods on Drug Release From PLGA-Based Microparticle Depot Formulations.
    Garner J; Skidmore S; Park H; Park K; Choi S; Wang Y
    J Pharm Sci; 2018 Jan; 107(1):353-361. PubMed ID: 29107048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse engineering of Perseris and development of compositionally equivalent formulations.
    Wang X; Bao Q; Wang R; Wan B; Wang Y; Qin B; Burgess DJ
    Int J Pharm; 2023 May; 639():122948. PubMed ID: 37044228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of PLGA Variability in Controlled Drug Release from Dexamethasone Intravitreal Implants.
    Costello MA; Liu J; Kuehster L; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F
    Mol Pharm; 2023 Dec; 20(12):6330-6344. PubMed ID: 37955890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles.
    Park K; Otte A; Sharifi F; Garner J; Skidmore S; Park H; Jhon YK; Qin B; Wang Y
    J Control Release; 2021 Jan; 329():1150-1161. PubMed ID: 33148404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protocol for assay of poly(lactide-co-glycolide) in clinical products.
    Garner J; Skidmore S; Park H; Park K; Choi S; Wang Y
    Int J Pharm; 2015 Nov; 495(1):87-92. PubMed ID: 26319639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLGA/PLA-Based Long-Acting Injectable Depot Microspheres in Clinical Use: Production and Characterization Overview for Protein/Peptide Delivery.
    Butreddy A; Gaddam RP; Kommineni N; Dudhipala N; Voshavar C
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
    Zhou J; Walker J; Ackermann R; Olsen K; Hong JKY; Wang Y; Schwendeman SP
    Mol Pharm; 2020 May; 17(5):1502-1515. PubMed ID: 32074448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.
    Li T; Chandrashekar A; Beig A; Walker J; Hong JKY; Benet A; Kang J; Ackermann R; Wang Y; Qin B; Schwendeman AS; Schwendeman SP
    Eur J Pharm Biopharm; 2021 Jan; 158():401-409. PubMed ID: 33122118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose.
    Sharifi F; Meqbil YJ; Otte A; Gutridge AM; Blaine AT; van Rijn RM; Park K
    Pharm Res; 2021 Jul; 38(7):1221-1234. PubMed ID: 34114163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tunable sustained release drug delivery system based on mononuclear aqueous core-polymer shell microcapsules.
    Abulateefeh SR; Alkawareek MY; Alkilany AM
    Int J Pharm; 2019 Mar; 558():291-298. PubMed ID: 30641178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of PLGA molecular weight differences on risperidone release from microspheres.
    Kohno M; Andhariya JV; Wan B; Bao Q; Rothstein S; Hezel M; Wang Y; Burgess DJ
    Int J Pharm; 2020 May; 582():119339. PubMed ID: 32305366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry fabrication of poly(dl-lactide-co-glycolide) microspheres incorporating a medium molecular drug by a ball mill method.
    Matsumoto A; Murakami M
    Drug Discov Ther; 2021 Mar; 15(1):20-27. PubMed ID: 33627576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of PLGA molecular weight distribution on leuprolide release from microspheres.
    Ochi M; Wan B; Bao Q; Burgess DJ
    Int J Pharm; 2021 Apr; 599():120450. PubMed ID: 33675924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.